Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Update on systemic treatment in early triple negative breast cancer
M. Nunez Abad, Sílvia Calabuig-Fariñas, M. Lobo de Mena, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1796-1796
Open Access | Times Cited: 132
Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
M. Nunez Abad, Sílvia Calabuig-Fariñas, M. Lobo de Mena, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 307-307
Open Access | Times Cited: 47
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
(2023)
Open Access | Times Cited: 36
Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy
Yedi Herdiana, Nasrul Wathoni, Dolih Gozali, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 879-879
Open Access | Times Cited: 30
Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways
Sushma Maharjan, Min‐Gu Lee, So Young Kim, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 672-672
Open Access | Times Cited: 18
Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression
Mengqi Wang, Shuting Lan, Wenqi Zhang, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 1985-2004
Open Access | Times Cited: 7
Vulnerability of Triple-Negative Breast Cancer to Saponin Formosanin C-Induced Ferroptosis
Hsin‐Chih Chen, Han-Hsuan Tang, Wei‐Hsiang Hsu, et al.
Antioxidants (2022) Vol. 11, Iss. 2, pp. 298-298
Open Access | Times Cited: 27
UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer
Gang Xiang, Shuxuan Wang, Ling Chen, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 5
Open Access | Times Cited: 23
Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy
Md Abdus Subhan, Vladimir P. Torchilin
Bioengineering (2024) Vol. 11, Iss. 8, pp. 830-830
Open Access | Times Cited: 4
Bio-nanocomplexes with autonomous O2 generation efficiently inhibit triple negative breast cancer through enhanced chemo-PDT
Zhihong Zeng, Zhou Wang, Simin Chen, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 15
Exosomes in triple negative breast cancer: From bench to bedside
Weiqiang Tang, Min Xia, Yajie Liao, et al.
Cancer Letters (2021) Vol. 527, pp. 1-9
Closed Access | Times Cited: 19
Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases
Lucas E. L. Terceiro, Nnamdi Ikeogu, Matheus Fabiao de Lima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12034-12034
Open Access | Times Cited: 7
Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer
Keiko Sato, Kentaro Miura, Shoma Tamori, et al.
Cancer Genomics & Proteomics (2024) Vol. 21, Iss. 3, pp. 316-326
Open Access | Times Cited: 2
Achillea fragrantissima (Forssk.) Sch.Bip Flower Dichloromethane Extract Exerts Anti-Proliferative and Pro-Apoptotic Properties in Human Triple-Negative Breast Cancer (MDA-MB-231) Cells: In Vitro and In Silico Studies
Nora Alshuail, Zeyad Alehaideb, Sahar S. Alghamdi, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 9, pp. 1060-1060
Open Access | Times Cited: 12
Exosomes modified with anti-MEK1 siRNA lead to an effective silencing of triple negative breast cancer cells
Débora Ferreira, Cátia Santos‐Pereira, Marta Costa, et al.
Biomaterials Advances (2023) Vol. 154, pp. 213643-213643
Open Access | Times Cited: 6
A Multifunctional Liposome for Synergistic Chemotherapy with Ferroptosis Activation of Triple-Negative Breast Cancer
Jingjing Chai, Jiawei Hu, Tao Wang, et al.
Molecular Pharmaceutics (2023) Vol. 21, Iss. 2, pp. 781-790
Closed Access | Times Cited: 6
LC–MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells
Alan Rubén Estrada-Pérez, Norbert Bakalara, J. Benjamín García‐Vázquez, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12074-12074
Open Access | Times Cited: 10
High extracellular glucose promotes cell motility by modulating cell deformability and contractility via the cAMP-RhoA-ROCK axis in human breast cancer cells
Mi-Jung Oh, Skylar R. Batty, Nayan Banerjee, et al.
Molecular Biology of the Cell (2023) Vol. 34, Iss. 8
Open Access | Times Cited: 5
Nucleolar and Coiled-Body Phosphoprotein 1 Is Associated With Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer
Sisi Chen, Ying Li, Muyao Wu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Management of triple-negative breast cancer in the era of novel therapies
Rakesh Sharma, Ajay Gogia
Cancer Research Statistics and Treatment (2021) Vol. 4, Iss. 4, pp. 668-676
Open Access | Times Cited: 10
Comprehensive Analysis of the Implication of PGRMC1 in Triple-Negative Breast Cancer
Xin Xu, Xiangyan Ruan, Ying Zhang, et al.
Frontiers in Bioengineering and Biotechnology (2021) Vol. 9
Open Access | Times Cited: 7
MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
Kristijan Skok, Lidija Gradišnik, Helena Čelešnik, et al.
Cells (2021) Vol. 11, Iss. 1, pp. 117-117
Open Access | Times Cited: 7
Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
Huan Zhang, Jinshun Xu, Binyang Gao, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 5
Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape
Xuemei Xie, Jangsoon Lee, Toshiaki Iwase, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 405-425
Closed Access | Times Cited: 3
Anticancer mechanism of 7-α-hydroxyfrullanolide on microtubules and computational prediction of its target binding in triple-negative breast cancer cells
Siriphorn Chimplee, Carl Smythe, Varomyalin Tipmanee, et al.
PeerJ (2022) Vol. 10, pp. e13508-e13508
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top